Low-Molecular-Weight Heparin and Recurrent Placenta-Mediated Pregnancy Complications: A Meta-analysis of Individual Patient Data From Randomised Controlled Trials
| Autor: | Évelyne Rey, Saskia Middeldorp, Jean-Christophe Gris, Risto Kaaja, Alain Mayhew, Marc A. Rodger, Carolien N H Abheiden, Ranjeeta Mallick, Paulien G. de Jong, David Petroff, Nicole Langlois, P. Dick Bezemer, Johanna I.P. de Vries, Shannon M. Bates, Ekkehard Schleussner, Annalisa Perna, Tim Ramsay, Ida Martinelli, Marion E. van Hoorn |
|---|---|
| Přispěvatelé: | Amsterdam Reproduction & Development (AR&D), Vascular Medicine, Other departments, ACS - Pulmonary hypertension & thrombosis, Ottawa Hospital Research Institute [Ottawa] (OHRI), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Obstetrics and gynaecology, MOVE Research Institute, ICaR - Ischemia and repair, Epidemiology and Data Science, ARD - Amsterdam Reproduction and Development, AMS - Growth and Development |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Pediatrics medicine.medical_specialty Placenta Diseases medicine.drug_class Birth weight Population Low molecular weight heparin 030204 cardiovascular system & hematology Thrombophilia law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Pre-Eclampsia law Pregnancy medicine Late Pregnancy Loss Humans education Adverse effect Randomized Controlled Trials as Topic education.field_of_study 030219 obstetrics & reproductive medicine Placental abruption business.industry Obstetrics Infant Newborn Obstetrics and Gynecology Heparin General Medicine Heparin Low-Molecular-Weight medicine.disease Delivery Obstetric 3. Good health Pregnancy Complications Relative risk Infant Small for Gestational Age Physical therapy Female business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology medicine.drug |
| Zdroj: | Obstetrical & gynecological survey, 72(3), 153-155. Lippincott Williams and Wilkins The Lancet The Lancet, Elsevier, 2016, 388 (10060), pp.2629-2641. ⟨10.1016/S0140-6736(16)31139-4⟩ Lancet, 388(10060), 2629-2641. Elsevier Limited Rodger, M A, Gris, J C, De Vries, J I P, Martinelli, I, Rey, É, Schleussner, E, Middeldorp, S, Kaaja, R, Langlois, N J, Ramsay, T, Mallick, R, Bates, S M, Abheiden, C N H, Perna, A, Petroff, D, De Jong, P, Van Hoorn, M E, Bezemer, P D & Mayhew, A D 2017, ' Low-Molecular-Weight Heparin and Recurrent Placenta-Mediated Pregnancy Complications : A Meta-analysis of Individual Patient Data from Randomised Controlled Trials ', Obstetrical and Gynecological Survey, vol. 72, no. 3, pp. 153-155 . https://doi.org/10.1097/01.ogx.0000513226.69777.83 Rodger, M A, Gris, J-C, de Vries, J I P, Martinelli, I, Rey, E, Schleussner, E, Middeldorp, S, Kaaja, R, Langlois, N J, Ramsay, T, Mallick, R, Bates, S M, Abheiden, C N H, Perna, A, Petroff, D, de Jong, P, van Hoorn, M E, Bezemer, P D & Mayhew, A D 2016, ' Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials ', Lancet, vol. 388, no. 10060, pp. 2629-2641 . https://doi.org/10.1016/S0140-6736(16)31139-4 Obstetrical and Gynecological Survey, 72(3), 153-155. Lippincott Williams and Wilkins |
| ISSN: | 0029-7828 0923-7577 0140-6736 |
| DOI: | 10.1016/S0140-6736(16)31139-4⟩ |
| Popis: | International audience; BACKGROUND:Placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate. These complications are leading causes of maternal, fetal, and neonatal morbidity and mortality in high-income countries. Affected women are at high risk of recurrence in subsequent pregnancies; however, effective strategies to prevent recurrence are absent. Findings from our previous study-level meta-analysis suggested that low-molecular-weight heparin reduced the risk of recurrent placenta-mediated pregnancy complications. However, we identified significant heterogeneity in the results, possibly due to trial design or inclusion criteria. To identify which patients benefit from, and which outcomes are prevented by, low-molecular-weight heparin, we did an individual patient data meta-analysis.METHODS:We did a systematic review in May, 2013, which identified eight eligible randomised trials done between 2000 and 2013 of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. We excluded studies on the basis of the wrong population, the study being ongoing, inability to confirm eligibility of participants, intervention stopped too early, and no response from the principal investigator. We requested individual patient data from the study authors for eligible women (women pregnant at the time of the study with a history of previous pregnancy that had been complicated by one or more of the following: pre-eclampsia, placental abruption, birth of an SGA neonate [ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|